No Data
Johnson & Johnson (JNJ.US) nicastrin monoclonal antibody injection is planned to be included in priority review.
On November 12th, the official website of CDE announced that Johnson & Johnson (JNJ.US) nicalizumab injection is expected to be included in the priority review.
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...
Express News | Nipocalimab Is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living With Moderate-to-Severe Sjögren's Disease
Express News | Stand up to Cancer Collaborates With Johnson & Johnson to Explore Targeted Therapies for Rare Disease Linked to Blood Cancers
STAND UP TO CANCER COLLABORATES WITH JOHNSON & JOHNSON TO EXPLORE TARGETED THERAPIES FOR RARE DISEASE LINKED TO BLOOD CANCERS
Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?